BERGANTINI, LAURA
 Distribuzione geografica
Continente #
EU - Europa 4.234
NA - Nord America 3.924
AS - Asia 349
SA - Sud America 14
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 4
Totale 8.541
Nazione #
US - Stati Uniti d'America 3.899
GB - Regno Unito 1.248
IT - Italia 1.218
SE - Svezia 616
FR - Francia 296
IE - Irlanda 260
DE - Germania 187
CN - Cina 155
UA - Ucraina 103
ES - Italia 93
FI - Finlandia 92
BE - Belgio 72
VN - Vietnam 64
IN - India 63
IR - Iran 27
CA - Canada 24
AU - Australia 10
TR - Turchia 10
CH - Svizzera 7
RU - Federazione Russa 7
BR - Brasile 6
EU - Europa 6
HK - Hong Kong 6
NL - Olanda 6
AT - Austria 4
JP - Giappone 4
MK - Macedonia 4
PK - Pakistan 4
PT - Portogallo 4
AR - Argentina 3
CL - Cile 3
EE - Estonia 3
NG - Nigeria 3
BD - Bangladesh 2
CY - Cipro 2
HR - Croazia 2
HU - Ungheria 2
KZ - Kazakistan 2
LT - Lituania 2
PH - Filippine 2
PL - Polonia 2
QA - Qatar 2
RO - Romania 2
BG - Bulgaria 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ID - Indonesia 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
LK - Sri Lanka 1
MM - Myanmar 1
MX - Messico 1
PE - Perù 1
RS - Serbia 1
SI - Slovenia 1
Totale 8.541
Città #
Southend 1.190
Chandler 634
Fairfield 613
Siena 280
Dublin 260
Ashburn 236
Woodbridge 230
Wilmington 223
Houston 212
Seattle 199
Princeton 186
Cambridge 179
Ann Arbor 127
Helsinki 91
Florence 74
Brussels 72
Málaga 68
Dong Ket 64
Jacksonville 64
Fremont 62
Beijing 60
San Mateo 59
San Diego 51
Dearborn 47
Rome 35
Milan 34
Washington 32
London 29
Gavirate 24
Shanghai 23
Tarazona 17
Chicago 13
Toronto 13
Nanjing 12
Zanjan 12
Aachen 11
Boardman 10
Chianciano Terme 10
Comun Nuovo 10
Grosseto 10
Hyderabad 10
Redwood City 10
Bangalore 9
Casier 9
Norwalk 9
San Francisco 9
Guangzhou 8
Izmir 8
Livorno 8
Nanchang 8
Naples 8
Padova 8
Prato 8
Brescia 7
Carrara 7
Chieti 7
Leawood 7
Hefei 6
Paris 6
Rubano 6
Saint-Fons 6
Winnipeg 6
Amsterdam 5
Andover 5
Bergamo 5
Dallas 5
Jinan 5
Mumbai 5
Ponte Buggianese 5
Scandicci 5
Verona 5
Arese 4
Arezzo 4
Barcelona 4
Bari 4
Bologna 4
Canberra 4
Chiswick 4
Cinisello Balsamo 4
Fiesole 4
Lamézia 4
Maddaloni 4
Melbourne 4
Paglieta 4
Pisa 4
Portogruaro 4
Potenza 4
Rieti 4
Torino 4
Vienna 4
Alghero 3
Athis-mons 3
Augsburg 3
Borgonovo Val Tidone 3
Boulder 3
Cascina 3
Duncan 3
Enugu 3
Falkenstein 3
Guagnano 3
Totale 5.897
Nome #
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 178
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 168
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 156
Peripheral biomarkers' panel for severe COVID-19 patients 156
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 155
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 149
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 148
Genetic mechanisms of critical illness in COVID-19 147
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 146
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 145
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 145
null 134
NK and NKT-like cells in granulomatous and fibrotic lung diseases 125
Serum amyloid A in patients with idiopathic pulmonary fibrosis 123
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 123
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 114
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 113
null 113
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 111
null 111
Prognostic bioindicators in severe COVID-19 patients 111
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 107
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 104
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 101
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 100
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 98
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 97
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 97
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 92
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 91
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 91
Serum amyloid A: A potential biomarker of lung disorders 90
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 90
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 89
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 87
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 86
Effects of rituximab therapy on B cell differentiation and depletion 86
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 82
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. 82
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 80
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 80
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 78
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 78
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 77
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 75
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 75
null 75
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 75
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 74
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 72
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 71
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 70
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 69
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 68
Mapping the human genetic architecture of COVID-19 67
Immunologic responses to antifibrotic treatment in IPF patients 65
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 64
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 63
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 63
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 63
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 62
null 61
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 61
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 59
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 59
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 59
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 59
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 58
null 58
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 58
Clinical phenotyping in sarcoidosis management 58
WES profiling of COVID-19 58
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 57
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 57
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 54
A first update on mapping the human genetic architecture of COVID-19 53
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 52
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 52
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 50
null 48
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 47
Serial autoantibody detection in interstitial lung diseases: should they be repeated at follow-up? 46
The Role of Galectins in Chronic Lung Allograft Dysfunction 46
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 45
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 45
An explainable model of host genetic interactions linked to COVID-19 severity 44
Serum Amyloid A in lung transplantation 44
High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool? 44
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy 43
Pathogen-sugar interactions revealed by universal saturation transfer analysis 42
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 42
Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review 42
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 41
The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis 41
Serial KL-6 measurements in COVID-19 patients 39
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 37
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 37
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis 37
Prognostic role of NK cell percentages in bronchoalveolar lavage from patients with different fibrotic interstitial lung diseases 36
Clinical utility of urinary concentrations of KL-6 as a predictive biomarker of developing bronchopulmonary dysplasia in preterm newborns 36
Totale 8.010
Categoria #
all - tutte 28.970
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.970


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019168 0 0 0 1 0 0 6 7 19 30 48 57
2019/2020893 47 41 20 94 79 83 85 103 101 98 51 91
2020/20212.166 64 100 101 271 185 246 160 256 217 147 217 202
2021/20222.319 175 263 201 156 112 103 98 109 105 294 266 437
2022/20232.873 177 299 337 276 160 478 304 270 228 131 134 79
2023/2024576 129 138 309 0 0 0 0 0 0 0 0 0
Totale 8.995